Status:

COMPLETED

Deep Clinical Trajectory Modeling to Optimize Accrual to Cancer Clinical Trials

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Cancer

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This study aims to evaluate the effectiveness of proactive notifications to treating oncologist to optimize participant accrual to clinical trials by utilizing the MatchMiner AI platform. This study c...

Detailed Description

The goal of this medical record data analysis and health system implementation study is to evaluate the effectiveness of proactive notifications to treating oncologist to optimize participant accrual ...

Eligibility Criteria

Inclusion

  • ≥ 18 years of age
  • adults with any type of cancer whose tumors underwent OncoPanel genomic sequencing from 2013-2022

Exclusion

  • ≤ 18 years of age.

Key Trial Info

Start Date :

January 30 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 15 2024

Estimated Enrollment :

20707 Patients enrolled

Trial Details

Trial ID

NCT06888089

Start Date

January 30 2023

End Date

July 15 2024

Last Update

March 21 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02215

Deep Clinical Trajectory Modeling to Optimize Accrual to Cancer Clinical Trials | DecenTrialz